4.8 Article

Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP)

Journal

GUT
Volume 71, Issue 5, Pages 854-863

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2021-324057

Keywords

gastric cancer; pre-malignancy; GI tract; surveillance

Funding

  1. National Research Foundation, Singapore
  2. Singapore Ministry of Health's National Medical Research Council [NMRC/TCR/009-NUHS/2013, NMRC/TCR/001-NUS/2007, MOH-OFLCG18May-0003]
  3. Biomedical Research Council (BMRC) [04/1/21/19/312]
  4. Singapore Cancer Syndicate (SCS) grant, Singapore [SCS-GN0015]

Ask authors/readers for more resources

This study found that gastric intestinal metaplasia (IM) is a significant risk factor for early gastric neoplasia (EGN) in regions with low-intermediate incidence of gastric cancer. Based on the results, it is recommended that high-risk patients (OLGIM III-IV) undergo endoscopic surveillance every 2 years, and intermediate-risk patients (OLGIM II) every 5 years.
Objective To investigate the incidence of gastric cancer (GC) attributed to gastric intestinal metaplasia (IM), and validate the Operative Link on Gastric Intestinal Metaplasia (OLGIM) for targeted endoscopic surveillance in regions with low-intermediate incidence of GC. Methods A prospective, longitudinal and multicentre study was carried out in Singapore. The study participants comprised 2980 patients undergoing screening gastroscopy with standardised gastric mucosal sampling, from January 2004 and December 2010, with scheduled surveillance endoscopies at year 3 and 5. Participants were also matched against the National Registry of Diseases Office for missed diagnoses of early gastric neoplasia (EGN). Results There were 21 participants diagnosed with EGN. IM was a significant risk factor for EGN (adjusted-HR 5.36; 95% CI 1.51 to 19.0; p<0.01). The age-adjusted EGN incidence rates for patients with and without IM were 133.9 and 12.5 per 100 000 person-years. Participants with OLGIM stages III-IV were at greatest risk (adjusted-HR 20.7; 95% CI 5.04 to 85.6; p<0.01). More than half of the EGNs (n=4/7) attributed to baseline OLGIM III-IV developed within 2 years (range: 12.7-44.8 months). Serum trefoil factor 3 distinguishes (Area Under the Receiver Operating Characteristics 0.749) patients with OLGIM III-IV if they are negative for H. pylori. Participants with OLGIM II were also at significant risk of EGN (adjusted-HR 7.34; 95% CI 1.60 to 33.7; p=0.02). A significant smoking history further increases the risk of EGN among patients with OLGIM stages II-IV. Conclusions We suggest a risk-stratified approach and recommend that high-risk patients (OLGIM III-IV) have endoscopic surveillance in 2 years, intermediate-risk patients (OLGIM II) in 5 years.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available